Citius Oncology (CTOR) Operating Income (2023 - 2026)
Citius Oncology (CTOR) posted quarterly Operating Income of -$28.6 million for Q1 2026, down 282.98% year-over-year from $15.6 million in Q1 2025, and down 444.78% quarter-over-quarter from -$5.3 million in Q4 2025.
Citius Oncology (CTOR) Operating Income (2023 - 2026) Analysis & Trends
Citius Oncology (CTOR) has reported Operating Income for 4 consecutive years, with -$28.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income fell 282.98% year-over-year to -$28.6 million; the TTM figure through Mar 2026 stood at -$43.5 million (down 55.22% YoY), while the FY2025 annual figure was -$23.5 million, down 14.34% from the prior year.
- Operating Income fell to -$28.6 million in Q1 2026 per CTOR's latest filing, from -$5.3 million in the prior quarter.
- Across five years, Operating Income topped out at -$147922.0 in Q1 2023 and bottomed at -$28.6 million in Q1 2026.
- Historically, Operating Income has averaged -$6.6 million across 4 years, with a median of -$4.9 million in 2025.
- Annual changes were most pronounced in 2024 — Operating Income slumped 6867.44% — and 2025, when it soared 64.43%.
- Citius Oncology's Operating Income stood at -$768931.0 in 2023, then sank by 731.67% to -$6.4 million in 2024, then gained by 17.87% to -$5.3 million in 2025, then slumped by 444.78% to -$28.6 million in 2026.
- Business Quant data shows CTOR's Operating Income at -$28.6 million in Q1 2026, -$5.3 million in Q4 2025, and -$4.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | -231.00 Mn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 837.00 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 1.26 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 330.80 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 6.30 Mn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 151.50 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 248.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Citius Oncology | 76.95 Mn | 76.95 Mn | 1.00 Mn | -8.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.61 Mn |
| Dec 31, 2025 | -5.25 Mn |
| Sep 30, 2025 | -4.71 Mn |
| Jun 30, 2025 | -4.94 Mn |
| Mar 31, 2025 | -7.47 Mn |
| Dec 31, 2024 | -6.39 Mn |
| Jun 30, 2024 | -13.90 Mn |
| Mar 31, 2024 | -268,429.00 |
| Sep 30, 2023 | -768,931.00 |
| Jun 30, 2023 | -199,554.00 |
| Mar 31, 2023 | -147,922.00 |